# T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)

> **NCT04093648** · PHASE1 · WITHDRAWN · sponsor: **Baylor College of Medicine**

## Conditions studied

- Hepatocellular Carcinoma
- Hepatoblastoma

## Interventions

- **GENETIC:** TEGAR T cells
- **DRUG:** Cytoxan
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT04093648
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-01
- **Primary completion:** 2023-02
- **Final completion:** 2038-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The key elements of this study were incorporated into another study.
- **Last updated:** 2020-05-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04093648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04093648, "T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04093648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*